JP Morgan Chase
IMUX icon

JP Morgan Chase’s Immunic IMUX Stock Holding History

JP Morgan Chase’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$586 Sell
38
-3
-7% -$37 ﹤0.01% 7398
2026
Q1 		$419 Hold
41
– – ﹤0.01% 7194
2025
Q4 		$217 Sell
41
-2,030
-98% -$14.9K ﹤0.01% 7152
2025
Q3 		$18.3K Buy
2,071
+1,200
+138% +$10.6K ﹤0.01% 6501
2025
Q2 		$6.08K Buy
871
+744
+586% +$6.83K ﹤0.01% 6395
2025
Q1 		$1.38K Sell
127
-495
-80% -$5.34K ﹤0.01% 6592
2024
Q4 		$6.22K Buy
622
+581
+1,417% +$7.32K ﹤0.01% 6478
2024
Q3 		$672 Hold
41
– – ﹤0.01% 6773
2024
Q2 		$452 Hold
41
– – ﹤0.01% 6698
2024
Q1 		$537 Hold
41
– – ﹤0.01% 6707
2023
Q4 		$611 Hold
41
– – ﹤0.01% 6902
2023
Q3 		$598 Hold
41
– – ﹤0.01% 6700
2023
Q2 		$1.02K Hold
41
– – ﹤0.01% 6452
2023
Q1 		$1K Sell
41
-2,449
-98% -$45.5K ﹤0.01% 6522
2022
Q4 		$35K Buy
2,490
+2,290
+1,145% +$62.5K ﹤0.01% 5723
2022
Q3 		$6K Sell
200
-79
-28% -$3.31K ﹤0.01% 6061
2022
Q2 		$9K Sell
279
-1,086
-80% -$69.6K ﹤0.01% 6049
2022
Q1 		$154K Buy
1,365
+239
+21% +$27.7K ﹤0.01% 5311
2021
Q4 		$108K Buy
1,126
+96
+9% +$8.64K ﹤0.01% 5643
2021
Q3 		$90K Buy
1,030
+179
+21% +$17.6K ﹤0.01% 5626
2021
Q2 		$104K Buy
851
+641
+305% +$88.7K ﹤0.01% 5528
2021
Q1 		$33K Sell
210
-38
-15% -$6.45K ﹤0.01% 5625
2020
Q4 		$38K Buy
248
+40
+19% +$7.18K ﹤0.01% 5211
2020
Q3 		$39K Sell
208
-86
-29% -$14.1K ﹤0.01% 5009
2020
Q2 		$36K Buy
+294
New +$29.9K ﹤0.01% 4925
2020
Q1 		– Sell
-1
Closed – – 5490
2019
Q4 		$0 Sell
1
-127
-99% -$10.6K ﹤0.01% 5744
2019
Q3 		$13K Buy
+128
New +$17.1K ﹤0.01% 5475
2019
Q2 		– Sell
-18
Closed -$1K – 5872
2019
Q1 		$1K Sell
18
-9
-33% -$791 ﹤0.01% 5690
2018
Q4 		$2K Buy
27
+9
+50% +$1.05K ﹤0.01% 5596
2018
Q3 		$2K Buy
18
+3
+20% +$7.83K ﹤0.01% 5608
2018
Q2 		$42K Buy
+15
New +$34.7K ﹤0.01% 5134
2018
Q1 		– Sell
-161
Closed -$383K – 5490
2017
Q4 		$383K Buy
161
+97
+152% +$214K ﹤0.01% 4180
2017
Q3 		$123K Buy
64
+61
+2,033% +$79.6K ﹤0.01% 4245
2017
Q2 		$4K Sell
3
-54
-95% -$72.1K ﹤0.01% 4780
2017
Q1 		$92K Sell
57
-25
-30% -$45.8K ﹤0.01% 4358
2016
Q4 		$142K Buy
+82
New +$180K ﹤0.01% 4286
2016
Q3 		– Sell
-2
Closed -$6K – 4663
2016
Q2 		$6K Sell
2
-2
-50% -$6.57K ﹤0.01% 4427
2016
Q1 		$14K Buy
4
+2
+100% +$6.95K ﹤0.01% 4174
2015
Q4 		$10K Buy
+2
New +$6.53K ﹤0.01% 4211

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

JP Morgan Chase's IMUX Position: Q2 2026 in Review

JP Morgan Chase reduced its Immunic (IMUX) stake by 7.3% in Q2 2026, selling an estimated $37 and leaving 38 shares worth $586. The position accounts for ﹤0.01% of the portfolio, ranked #7398.

JP Morgan Chase first reported a position in IMUX in Q4 2015 and has held it in 39 quarters since. The position peaked at $383K in Q4 2017. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • JP Morgan Chase held 38 shares of Immunic worth $586 as of Q2 2026.
  • JP Morgan Chase sold 3 Immunic shares in Q2 2026, an estimated $37.
  • Immunic made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7398 holding.
  • JP Morgan Chase first reported a position in Immunic in Q4 2015 and has held it in 39 quarters since.
  • JP Morgan Chase's Immunic position peaked at $383K in Q4 2017.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.